CRSP FY 2019 Earnings Report — CRISPR Therapeutics AG Revenue & Financial Results | Market Cap Arena

CRISPR Therapeutics AGCRSP

FY 2019 Earnings

Reported February 12, 2020

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2019	Prior Q	FY 2018	QoQ Change	YoY Change
Revenue	$290M	—	$3M	—	9169.8%
Op. Income	$47M	—	-$159M	—	129.4%
Gross Margin	38.1%	—	-3541.9%	—	3580.0pp
Net Margin	23.1%	—	-5281.1%	—	5304.2pp
EPS (Diluted)	$1.17	—	$-3.44	—	134.0%
Free Cash Flow	$50M	—	-$99M	—	150.5%

Revenue Flow

Item	Amount
REVENUE	$290M
Cost of Revenue	$179M
GROSS PROFIT	$110M
R&D Expenses	$179M
Selling & Marketing	$0
General & Administrative	$63M
SG&A Expenses	$63M
Other Expenses	-$179M
Operating Expenses	$63M
Cost & Expenses	$243M
OPERATING INCOME	$47M
Other Income/Expenses	$21M
INCOME BEFORE TAX	$67M
Income Tax Expense	$448.0K
Net Income from Continuing Ops	$67M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$67M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$67M
D&A	$5M
EBIT	$47M
EBITDA	$51M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$290M
Cost of Revenue	$179M
GROSS PROFIT	$110M
R&D Expenses	$179M
Selling & Marketing	$0
General & Administrative	$63M
SG&A Expenses	$63M
Other Expenses	-$179M
Operating Expenses	$63M
Cost & Expenses	$243M
OPERATING INCOME	$47M
Other Income/Expenses	$21M
INCOME BEFORE TAX	$67M
Income Tax Expense	$448.0K
Net Income from Continuing Ops	$67M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$67M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$67M
D&A	$5M
EBIT	$47M
EBITDA	$51M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$67M
Depreciation & Amortization	$5M
Stock-Based Compensation	$44M
Deferred Income Tax	$0
Other Non-Cash Items	-$11M
Change in Working Capital	-$48M
OPERATING CASH FLOW	$57M
Capital Expenditure	-$7M
Acquisitions (Net)	$0
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	$8M
NET CASH FROM INVESTING	$1M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$16M
NET CASH FROM FINANCING	$431M
FREE CASH FLOW	$50M
Net Change in Cash	$489M

Balance Sheet

Item	Amount
Cash & Equivalents	$944M
Short-Term Investments	$0
Net Receivables	$99.0K
Inventory	$0
Other Current Assets	$0
TOTAL CURRENT ASSETS	$988M
PP&E (Net)	$73M
Goodwill	$0
Intangible Assets	$235.0K
Long-Term Investments	$5M
Tax Assets	-$5M
Other Non-Current Assets	$6M
TOTAL NON-CURRENT ASSETS	$79M
TOTAL ASSETS	$1.1B
Account Payables	$6M
Short-Term Debt	$8M
Deferred Revenue	$960.0K
Other Current Liabilities	$26M
TOTAL CURRENT LIABILITIES	$57M
Long-Term Debt	$0
Deferred Revenue NC	$12M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$14M
TOTAL NON-CURRENT LIABILITIES	$70M
TOTAL LIABILITIES	$127M
Common Stock	$2M
Additional Paid-In Capital	$1.2B
Retained Earnings	-$225M
Treasury Stock	-$63.0K
Accum. Other Comp. Income	$7.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$939M
Minority Interest	$0
TOTAL EQUITY	$939M
TOTAL LIABILITIES & EQUITY	$1.1B
Total Debt	$53M
Net Debt	-$891M